Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026)
Arbutus Biopharma (ABUS) posted Change in Receivables of $178.7 million for Q1 2026, up 138458.91% sequentially from $129000.0 in Q4 2025, and up 14667.32% YoY from N/an in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Change in Receivables for 14 years, with the latest figure at $178.7 million in Q1 2026.
- Quarterly Change in Receivables rose 14667.32% year-over-year to $178.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.6 million (up 18761.76% YoY) and the FY2025 annual result came in at -$1.4 million, down 317.22% from the prior year.
- Change in Receivables advanced to $178.7 million in Q1 2026 per ABUS's latest filing, from $129000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $178.7 million in Q1 2026 and troughed at -$1.2 million in Q1 2025.
- A 5-year average of $10.5 million and a median of -$120000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2026: Change in Receivables plunged 644.0% in 2024, then soared 14667.32% in 2026.
- Over 5 years, Change in Receivables stood at -$483000.0 in 2022, then advanced by 18.22% to -$395000.0 in 2023, then jumped by 302.78% to $801000.0 in 2024, then plunged by 83.9% to $129000.0 in 2025, then soared by 138458.91% to $178.7 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $178.7 million, $129000.0, and -$120000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | 632,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 632,000.00 |
| Mar 31, 2026 | 178.74 Mn |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Jun 30, 2025 | -157,000.00 |
| Mar 31, 2025 | -1.23 Mn |
| Dec 31, 2024 | 801,000.00 |
| Sep 30, 2024 | -159,000.00 |
| Jun 30, 2024 | -372,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Dec 31, 2023 | -395,000.00 |
| Sep 30, 2023 | -443,000.00 |
| Jun 30, 2023 | -50,000.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | -483,000.00 |
| Sep 30, 2022 | -135,000.00 |
| Jun 30, 2022 | 657,000.00 |
| Mar 31, 2022 | 414,000.00 |
| Dec 31, 2021 | -768,000.00 |
| Sep 30, 2021 | 369,000.00 |